Boadie Dunlop
Chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia at Augusta University; Adjunct Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine
Data updated
Research Footprint
Boadie Dunlop appears in 9 tracked papers (2017–2025), most studied alongside Psilocybin, MDMA and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and PTSD.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Katharine Dunlop, Jessica Maples-Keller and Guy Goodwin.
Background & Research
Boadie W. Dunlop, MD, MSCR is a psychiatrist and clinical researcher specializing in mood disorders, anxiety disorders, and post-traumatic stress disorder. He previously spent 28 years at Emory University, where he directed the Mood and Anxiety Disorders Program and co-directed the Emory Center for Psychedelics and Spirituality, and he now serves as chair of Psychiatry and Health Behavior at the Medical College of Georgia. His research portfolio includes more than 70 NIH- and industry-funded studies, including trials involving MDMA and psilocybin.
Key Impact
He is a clinician-researcher whose work on MDMA, psilocybin, ketamine, and personalized treatment for depression, anxiety, and PTSD has helped advance modern psychedelic psychiatry.
Collaboration Network
29 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Boadie Dunlop is associated with.
Medical College of Georgia at Augusta University
The Medical College of Georgia (MCG) is the medical school of Augusta University, a public medical school based in Augusta, Georgia, United States, that educates MD students and operates multiple campuses and clinical training sites across the state.
View stakeholder →Emory University
academicThe Center for Psychedelics and Spirituality at Emory University combines expertise in psychiatry with spiritual health to better understand the therapeutic promise of psychedelics as medicine. Launched at the end of 2022, the group works towards making psychedelic-assisted therapies more effective within a wide cultural and spiritual context.
View stakeholder →